Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase 3-studie av IV humant plasma-avledet C1-esterasehemmerkonsentrat hos pasienter med medfødt C1-INH-mangel for behandling og pre-prosedyre forebygging av akutte arvelige angioødemangrep

5. november 2026 oppdatert av: Octapharma

Prospektiv, multisenter, randomisert, dobbeltblind, parallell gruppe, placebokontrollert, effekt og sikkerhet Fase 3-studie av et intravenøst ​​humant plasma-avledet C1-esterasehemmerkonsentrat (C1-INH) hos deltakere med medfødt C1-INH-mangel for behandling og Pre-prosedyre forebygging av akutte arvelige angioødemanfall

Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

124

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

  • Albania
      • Tirana, Albania
        • Tilbaketrukket
        • Octapharma Research Site
  • Argentina
      • Rosario, Argentina
        • Rekruttering
        • Octapharma Research Site
  • Armenia
      • Yerevan, Armenia
        • Rekruttering
        • Octapharma Research Site
  • Bulgaria
      • Sofia, Bulgaria, 1431
        • Rekruttering
        • Octapharma Research Site
  • Forente stater
    • Colorado
      • Centennial, Colorado, Forente stater, 80112
        • Tilbaketrukket
        • Octapharma Research Site
    • Michigan
      • Farmington Hills, Michigan, Forente stater, 48334
        • Tilbaketrukket
        • Octapharma Research Site
    • Ohio
      • Toledo, Ohio, Forente stater, 43617
        • Tilbaketrukket
        • Octapharma Research Site
  • India
      • Bangalore, India, 560017
        • Har ikke rekruttert ennå
        • Octapharma Research Site
      • Chhatrapati Sambhajinagar, India, 431003
        • Har ikke rekruttert ennå
        • Octapharma Research Site, Chhatrapati Sambhajinagar
      • Hyderabad, India, 500003
        • Har ikke rekruttert ennå
        • Octapharma Research Site
      • Patna, India, 801507
        • Har ikke rekruttert ennå
        • Octapharma Research Site
      • Srinagar, India, 190010
        • Har ikke rekruttert ennå
        • Octapharma Research Site
    • Maharashtra
      • Pune, Maharashtra, India, 411040
        • Har ikke rekruttert ennå
        • Octapharma Research Site
  • Mexico
      • Mexico City, Mexico, 06720
        • Har ikke rekruttert ennå
        • Octapharma Research Site
      • México, Mexico
        • Har ikke rekruttert ennå
        • Octapharma Research Site
  • Montenegro
      • Podgorica, Montenegro
        • Tilbaketrukket
        • Octapharma Research Site
  • Peru
      • Lima, Peru, 15001
        • Rekruttering
        • Octapharma Research Site 5103
      • Lima, Peru, 15001
        • Rekruttering
        • Octapharma Research Site 5102
  • Romania
      • Cluj-Napoca, Romania, 400162
        • Tilbaketrukket
        • Octapharma Research Site
  • Serbia
      • Kragujevac, Serbia, 11221
        • Tilbaketrukket
        • Octapharma Research Site
  • Tyrkia (Türkiye)
      • Ankara, Tyrkia (Türkiye)
        • Har ikke rekruttert ennå
        • Octapharma Research Site
      • Istanbul, Tyrkia (Türkiye)
        • Har ikke rekruttert ennå
        • Octapharma Research Site
      • Izmir, Tyrkia (Türkiye)
        • Tilbaketrukket
        • Octapharma Research Site
      • Sakarya, Tyrkia (Türkiye)
        • Har ikke rekruttert ennå
        • Octapharma Research Site
  • Ukraina
      • Kyiv, Ukraina, 03057
        • Rekruttering
        • Octapharma Research Site
      • Lviv, Ukraina, 79035
        • Har ikke rekruttert ennå
        • Octapharma Research Site
      • Lviv, Ukraina, 79010
        • Tilbaketrukket
        • Octapharma Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

2 år og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Is at least 18 years of age (applicable for 1st study phase) or is at least 2 years of age (applicable for 2nd study phase)

  2. Has confirmed diagnosis of HAE type I or II

  3. Has had at least 3 moderate or severe HAE attacks (excluding extremity attacks) in the last 3 months before the Screening Visit. For participants ≥2 and ≤12 years of age, has had at least 1 moderate or severe HAE attack (excluding extremity attacks) in the last 6 months before Screening Visit

  4. Has a documented congenital C1-INH functional activity <50% with or without C1-INH deficiency and C4 antigen level below the laboratory reference range

  5. Participant or the participant's legally authorized representative(s) has signed informed consent (as required by local law), with the assent of participants legally capable of providing it, as applicable

  6. States willingness to comply with all study procedures and availability for the duration of the study

  7. If the participant is of childbearing potential (CBP), has a negative pregnancy test and must have been using a highly effective method of contraception and continue to do so until at least 2 weeks after their last dose (for both blinded and open-label doses of IMP). Not of CBP is defined as surgically sterilized (hysterectomy, bilateral oophorectomy) or who are postmenopausal (defined as women with no menses for 12 months without an alternative medical cause). Highly effective methods of contraception:

    • Combined hormonal contraception (estrogens and progesterone) methods such as oral, implantable, intravaginal, injectable, or transdermal contraceptives at a stable dose for a minimum of 1 full cycle (hormonal contraceptives must inhibit ovulation) and for at least 4 weeks before screening
    • Progesterone only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
    • Intrauterine device
    • Intrauterine hormone-releasing system inserted at least 4 weeks before screening
    • Bilateral tubal ligation/occlusion or vasectomized partner (with surgical success confirmed by medical assessment) OR Agrees to abstain from heterosexual intercourse during study participation and to use a highly effective contraceptive (as described above) as backup if they become sexually active during the study. Abstinence is only acceptable if this is the participant's usual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception
    • Note: If a participant of CBP has a positive or suspected positive urine pregnancy test within 72 hours prior to treatment, a serum pregnancy test will be required
    • Male participants must not plan to father a child or donate sperm for 90 days after their last dose of study drug (for both blinded and open-label doses of the IMP). However, there are no official contraception requirements for male participants during the study.

Inclusion Criteria for IMP Dosing for QAT:

  1. Has confirmed QAT per definition criteria
  2. Has a swelling episode that is new and not the continuation of a previous HAE attack

Exclusion Criteria:

  1. Has a history of clinically relevant antibody development against C1-INH
  2. Has a medical history consistent with Type 3 HAE (i.e., onset at age above 40 year, no family history, no known HAE mutation, low C1q level in plasma)
  3. Has a history of allergic reaction to C1-INH or other blood/plasma product
  4. Has a history of B-cell malignancy that was unresolved in the past 5 years
  5. Has a narcotic and/or alcoholic addiction
  6. Has participated in any other investigational drug evaluation within 30 days before screening
  7. Is pregnant or breastfeeding
  8. Has any clinically significant medical or psychiatric condition that, in the investigator's opinion would interfere with the participant's ability to participate in the study
  9. Has a history of thromboembolic events (TEEs), myocardial infarction, unstable angina pectoris, critical aortic stenosis, cerebrovascular accident, transient ischemic attack, severe peripheral vascular disease, or disseminated intravascular coagulation within one year before screening
  10. (applicable until IDMC review of the interim preliminary safety and efficacy data): has clinically significant derangement in measurements of cardiovascular status (i.e. uncontrolled arterial hypertension, cardiac insufficiency New York Heart Association (NYHA) class III-IV), pulmonary status (i.e., COPD GOLD classification 3 and 4, severe asthma) and renal status (i.e., eGFR below 90 ml/min per 1.73 m2)

Exclusion Criteria for IMP Dosing for QAT:

  1. Has received blood or a blood product for prophylactic or acute treatment with any C1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykinin and kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), or treatment with tranexamic acid within 14 days before dosing with the IMP (or is not willing to abstain from these medications throughout the study)
  2. started or changed hormone replacement therapy or selective estrogen receptor modulators (e.g., tamoxifen) within 14 days before IMP dosing
  3. Started or changed androgen therapy (e.g. testosterone, dehydro- epiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) within 14 days before IMP dosing or is not willing to maintain a stable dose throughout the study
  4. Started or changed the dose of monoclonal antibodies e.g. lanadelumab within 11 weeks before dosing or not willing to maintain a stable dose throughout the study
  5. Has used narcotic pain medications or non-opioid analgesics within 7 days before IMP dosing for a QAT
  6. Has received OCTA-C1-INH within 14 days before IMP dosing

Exclusion Criteria for IMP Dosing for PK:

  1. Has received blood or a blood product for prophylactic or acute treatment with any C1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykinin and kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), or treatment with tranexamic acid within 14 days before dosing with the IMP (or is not willing to abstain from these medications throughout the study)
  2. Is receiving hormone replacement therapy or selective estrogen receptor modulators (e.g., tamoxifen) and has had their dose changed within 14 days before IMP dosing
  3. Is receiving or has received androgen therapy (e.g., testosterone, dehydroepiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) IN ANY DOSE within 14 days before dosing
  4. Started or changed the dose of monoclonal antibodies e.g lanadelumab within 11 weeks before dosing or not willing to maintain a stable dose throughout the study
  5. Has used narcotic pain medications or non-opioid analgesics within 7 days before IMP dosing
  6. Has received IMP within 14 days before IMP dosing
  7. Has planned dental, medical, or surgical procedures during the PK Period that will require pre-procedural prevention

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: OCTA-C1-INH

OCTA-C1-INH injection, 20IU/kg BW after first qualifying attack. Treatment to be administered to blinded as well as open-label subjects.
Legemiddel: OCTA-C1-INH

OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW)
Placebo komparator: Placebo

0.1 mL/kg BW 0.9% sodium chloride solution injection after first qualifying attack. Only blinded subjects to receive.
Annen: Placebo

0.1 mL/kg BW 0.9% sodium chloride injection

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Time (h) to beginning of unequivocal symptom relief at the defining site in blinded participants.
Tidsramme: Within 4 hours after injection

Patient will rate symptom relief for the defining attack site (site of swelling or pain) from 15 minutes after start of the IMP injection every 15 minutes over 4 hours. Unequivocal relief is defined as having 3 consecutive reports of "absent now but present before," "absent now and absent before", or "present, symptoms better" on the 5-grade SRRS.

This measure will also be used for the secondary outcomes in a different context.
Within 4 hours after injection

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Percentage of participants responding to treatment
Tidsramme: within 4 hours after injection

Percentage of patients responding to treatment, defined as beginning of unequivocal symptom relief at the defining site within 4 hours after injection (once per participant after first qualifying attack in the study). Unequivocal relief is defined as having 3 consecutive reports of "absent now but present before," "absent now and absent before", or "present, symptoms better" on the 5-grade symptom relief rating.
within 4 hours after injection
Time to beginning of unequivocal symptom relief at all sites involved
Tidsramme: Within 4 hours after injection

Time to the beginning of unequivocal symptom relief at all sites involved within 4 hours after injection. Unequivocal relief is defined as having 3 consecutive reports of "absent now but present before," "absent now and absent before", or "present, symptoms better" on the 5-grade symptom relief rating.
Within 4 hours after injection
Changes in symptom severity at the defining site by VAS severity rating
Tidsramme: Within 4 hours after injection

Changes in symptom severity at the defining site by visual analog scale (VAS) rating from pre-injection over 4 hours after injection. The VAS is a self-reported 0-100 pain and swelling rating scale.
Within 4 hours after injection

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Octapharma

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

30. april 2024

Primær fullføring (Antatt)

1. desember 2026

Studiet fullført (Antatt)

1. juni 2027

Datoer for studieregistrering

Først innsendt

11. januar 2024

Først innsendt som oppfylte QC-kriteriene

5. april 2024

Først lagt ut (Faktiske)

12. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • CONE-02

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere